The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.
NCT04691323
Anemia, Anemia, Hemolytic
Chicago, Illinois, United States
View Trial DetailsNCT Number: NCT02239016
This study aims to study the temporal course of sickle nephropathy and assess novel biomarkers that can predict patients prone to nephropathy.
Looking for future studies?
Notify MeAll sexes
Observational
Emory University (Children's Healthcare of Atlanta Pediatric Hospital), Atlanta, Georgia, United States
Sickle cell disease causes kidney damage that gets worse with increasing age, leading to chronic kidney disease and kidney failure in nearly one third of patients with sickle cell disease. Some patients develop kidney damage at a young age and others show mild kidney damage at older ages. We do not know the natural progression of kidney damage in sickle cell disease patients, nor do we know who is more prone to develop severe kidney damage. Therefore, currently, there are no preventative measures or treatments for sickle cell related kidney disease. The purpose of this research study is to collect data that will help in assessing the progression of kidney damage in sickle cell disease, develop novel urine and blood tests that can predict kidney damage early, and developing treatment ideas for intervention and prevention of kidney damage that eventually leads to kidney failure.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline through 36 months
Time frame: baseline, year 1, year 2 and year 3
Children's Hospital Medical Center, Cincinnati
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04691323
Anemia, Anemia, Hemolytic
Chicago, Illinois, United States
View Trial DetailsNCT04688411
Anemia, Anemia, Hemolytic
Chicago, Illinois, United States
View Trial DetailsNCT05405114
Anemia, Anemia, Hemolytic
Mobile, Alabama, United States
View Trial DetailsNCT07721155
Anemia, Anemia, Hemolytic
Amsterdam, Netherlands
View Trial Details